Mar 06, 2026 | FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet

The FDA told uniQure it is not convinced AMT-130provides any therapeutic benefit in Huntington’s disease — the program now faces a full Phase Three, raising the evidentiary floor for all CNS gene therapy. Moderna jumped fourteen percent on forty-nine percent melanomarecurrence reduction from mRNA-4157 plus Keytruda, combined with resolution of its LNP patent overhang. Servier acquires Day One Biopharmaceuticals fortwo-and-a-half billion dollars; Zealand’s petrelintide obesity data triggers a thirty-five percent drop; Lantheus’s PYLARIFY TruVu wins FDA approval